HomeNewsInhalers

Inhalers

Jump to

Nomura upgrades Lupin to buy, raises target to Rs 2149/sh

Significant value-accretive acquisitions and visibility to sustain growth by moving up the complexity levels (inhalers and biosimilars) could justify a higher valuation multiple, it feels.
Cipla falls 3%; CLSA downgrades to sell, target Rs 619

Shares of Cipla fell 2.6 percent intraday Friday. Brokerage CLSA downgraded the stock to a sell from underperform with target price of Rs 619 as it believes results of transformation could take longer than expected.
Cipla Q3 PAT may rise 6.1% to Rs 360 cr: CNBC-TV18 poll

Analysts feel profit after tax of Cipla may come in as low as Rs 300 crore during the quarter due to margin pressure.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Inhalers

Nomura upgrades Lupin to buy, raises target to Rs 2149/sh

Cipla falls 3%; CLSA downgrades to sell, target Rs 619

Cipla Q3 PAT may rise 6.1% to Rs 360 cr: CNBC-TV18 poll